戻る Agenda
Session 1: Keynote Address: The Value of Project Management in the Increasingly Complex Healthcare Ecosystem & Welcoming Remarks
Session Chair(s)
Leigh Shultz, PhD, PMP
Executive Director, Human Health Commercial Operations
Merck & Co., Inc., United States
With the cost of healthcare and the long timelines for development of new products continually in the spotlight, perhaps never more so than during the COVID-19 pandemic, multiple studies have evaluated the investment required by pharmaceutical and biotech companies to bring a new product to market, with recent estimates ranging from $300 million to $2.8 billion. The timelines and cost are driven in part by the complexity of product development, which requires the careful integration of many disparate activities into a well-orchestrated and executable plan. A recent perspective by Wagner, et al. in Nature Reviews Drug Discovery noted that “in the absence of strong coordination and communication, the complex and dynamic process of drug development frequently fails.” Project Managers in this ecosystem play an increasingly important role in bringing new therapies to patients as quickly as possible and minimizing failure.
Learning Objective : - Explain some of the recent dynamics driving the continued increase in complexity, cost, and timelines in product development
- Discuss the value of integrated planning and careful management of execution
- Discuss the important role that project managers play in managing complexity and enabling execution
Speaker(s)
Speaker
Sandy Milligan, JD, MD
Innovex Strategies, United States
Board of Director Member, Gossamer Bio; Principal
Mark Kryah, PMP
Ultragenyx Pharmaceutical Inc., United States
Executive Director, Program Team Leader, Program and Portfolio Management
DIA Welcome
Tamei Elliott, MS
DIA, United States
Associate Director, Scientific Programs